Drugs / KAND145
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06063343 | Nov 2023 → Apr 2024 | ovarian cancer | Novakand Pharma AB | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KAND145 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06063343 ↗ |
| Route | Oral | “This is a Phase 1, first-in-human (FIH), single-center, placebo-controlled, randomized, double-blind study in healthy subjects to evaluate safety, tolerability, PK, food effect...” NCT06063343 ↗ |